Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and <i>CYP2C19</i> Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

DOI Web Site Web Site 被引用文献4件
  • JK Hicks
    Department of Pharmacy Cleveland Clinic, Cleveland, Ohio, USA; Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA; and Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Cleveland Ohio USA
  • JR Bishop
    University of Minnesota College of Pharmacy, Department of Experimental and Clinical Pharmacology Minneapolis Minnesota USA
  • K Sangkuhl
    Department of Genetics Stanford University Stanford California USA
  • DJ Müller
    Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto Toronto Ontario Canada
  • Y Ji
    Department of Laboratory Medicine and Pathology Division of Laboratory Genetics Mayo Clinic Rochester Minnesota USA
  • SG Leckband
    Veterans Affairs San Diego Healthcare System, Mental Health Care Line, University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences and Department of Psychiatry San Diego California USA
  • JS Leeder
    Division of Clinical Pharmacology Toxicology & Innovative Therapeutics, Children's Mercy Hospital, Kansas City, Missouri and Department of Pediatrics, University of Missouri‐Kansas City Kansas City Missouri USA
  • RL Graham
    Philadelphia Veterans Affairs Medical Center Philadelphia Pennsylvania USA
  • DL Chiulli
    Veterans Affairs Palo Alto Health Care System, San Jose Division San Jose California USA
  • A LLerena
    CICAB Clinical Research Center Extremadura University Hospital and Medical School Badajoz Spain
  • TC Skaar
    Division of Clinical Pharmacology Department of Medicine Indiana University School of Medicine Indianapolis Indiana USA
  • SA Scott
    Department of Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai New York New York USA
  • JC Stingl
    Federal Institute of Drugs and Medical Devices Bonn Germany
  • TE Klein
    Department of Genetics Stanford University Stanford California USA
  • KE Caudle
    Department of Pharmaceutical Sciences St. Jude Children's Research Hospital Memphis Tennessee USA
  • A Gaedigk
    Division of Clinical Pharmacology Toxicology & Innovative Therapeutics, Children's Mercy Hospital, Kansas City, Missouri and Department of Pediatrics, University of Missouri‐Kansas City Kansas City Missouri USA

抄録

<jats:p>Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. <jats:italic>CYP2D6</jats:italic> and <jats:italic>CYP2C19</jats:italic> polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on <jats:italic>CYP2D6</jats:italic> and/or <jats:italic>CYP2C19</jats:italic> genotype (updates at <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pharmgkb.org">www.pharmgkb.org</jats:ext-link>).</jats:p>

収録刊行物

被引用文献 (4)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ